 Clinical Study
October 29, 2024
Overview Wave Life Sciences has announced a significant milestone in gene therapy through its RestorAATion-2 trial, showcasing the first-ever therapeutic RNA editing in humans. This innovative approach targets Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder linked to lung and liver disease, through its ...
|
Partnership
October 29, 2024
Vimeo’s Cinematic Ambitions Amid Market Headwinds: A Balancing ActIn a bid to solidify its standing in the competitive video-on-demand market, Vimeo has recently announced a strategic partnership with the European Film Academy (EFA) aimed at celebrating and promoting the art of filmmaking. This initiative will se...
|
Contract
October 28, 2024
iPower Inc. Achieves Key Milestone with First Purchase Order Shipment from Vietnam In a significant development within the e-commerce landscape, iPower Inc. (Nasdaq: IPW), a technology and data-driven ecommerce services provider, has announced the successful shipment of its first purchase order (PO) from Vietnam. Th...
|
|
 Business Update
October 29, 2024
In an era when sustainability is rapidly becoming a central focus for industries worldwide, Bentley Systems Incorporated is making significant strides in providing innovative solutions for reducing the carbon footprint of infrastructure projects. The company has unveiled new carbon analysis functionalities aimed at ...
 Contract
October 29, 2024
In an increasingly competitive landscape, maintaining long-standing partnerships is a testament to a company’s resilience and commitment to excellence. Urgently, a leading provider of roadside assistance technology and services, has once again proven its mettle by renewing its contract with a prominent global car ...
|
|
Our most Popular Articles
|
Product Service News
September 13, 2024
As the leaves turn and autumn whispers the arrival of new adventures, the RV industry gears up for one of its most anticipated events: the Hershey RV Show. This year, Winnebago Industries Inc. (NYSE: WGO) stands at the forefront of innovation and bold design, revealing a staggering lineup of nearly 150 new models fr...
|
Clinical Study
August 22, 2024
In an exciting development in the field of obesity treatment, Skye Bioscience has announced the launch of its Phase 2 clinical trial, known as the CBeyond trial, to evaluate the efficacy and safety of its innovative CB1 inhibitor, nimacimab. This clinical trial aims to address one of the most pressing health concern...
|
Product Service News
September 13, 2024
CSIMarket.com Factual - September 11, 2024 B2Gold Corp Engages in Accord with the Government of Mali Regarding the Fekola Complex In the year of our Lord, 2024, on the 11th day of September, B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G), a Canadian entity based in the city of Vancouver, Britons of C...
|
|
|
Company News
|
Partnership
October 29, 2024
Vimeo’s Cinematic Ambitions Amid Market Headwinds: A Balancing ActIn a bid to solidify its standing in the competitive video-on-demand market, Vimeo has recently announced a strategic partnership with the European Film Academy (EFA) aimed at celebrating and promoting the art of filmmaking. This initiative will se...
|
Contract
October 28, 2024
iPower Inc. Achieves Key Milestone with First Purchase Order Shipment from Vietnam In a significant development within the e-commerce landscape, iPower Inc. (Nasdaq: IPW), a technology and data-driven ecommerce services provider, has announced the successful shipment of its first purchase order (PO) from Vietnam. Th...
|
Business Update
October 28, 2024
Adicet Bio Secures FDA Approval for Pioneering Trials of ADI-001 in Rare Autoimmune Disorders: Idiopathic Inflammatory Myopathy and Stiff Person Syndrome to ADI-001 and Its Potential Impact In an exciting development for the treatment of rare autoimmune disorders, Adicet Bio, Inc. a leading clinical-stage biotechn...
|
|
|
Company News
 Clinical Study
October 28, 2024
|
Company News
 Product Service News
October 28, 2024
|
Company News
 Product Service News
October 28, 2024
|
More Company News
|
Product Service News
October 28, 2024
|
Business Update
October 28, 2024
|
Product Service News
October 28, 2024
|
Product Service News
October 28, 2024
|
Clinical Study
October 28, 2024
|
Clinical Study
October 28, 2024
|
Clinical Study
October 28, 2024
|
Announcement
October 28, 2024
|
Announcement
October 28, 2024
|
Product Service News
October 28, 2024
|
|
|
|
Related News
|
Contract
|
Product Service News
|
|
Stocks
|
Announcement
|
Business Update
|
Financing Agreement
|
|
|
|
Business News
|
|
Business Update
In an era when sustainability is rapidly becoming a central focus for industries worldwide, Bentley Systems Incorporated is making significant strides in providing innovative solutions for reducing the carbon footprint of infrastructure projects. The company has unveiled new carbon analysis functionalities aimed at ...
|
|
Contract
In an increasingly competitive landscape, maintaining long-standing partnerships is a testament to a company’s resilience and commitment to excellence. Urgently, a leading provider of roadside assistance technology and services, has once again proven its mettle by renewing its contract with a prominent global car ...
|
 Product Service News
In a bold move to reshape the hospitality industry, Future Hospitality Ventures Holdings Inc. (FHV), a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), has announced a new initiative leveraging artificial intelligence aimed at transforming operations in the $300 billion hospitality market. The initiative, revea...
|
|
Contract
Driving Forward: Leading Chinese Auto Finance Provider Adopts NETSOL s Transcend Finance Platform October 16, 2024 - ENCINO, Calif. - In a strategic move that underscores the growing influence and reach of global financial technology solutions, NETSOL Technologies, Inc. (Nasdaq: NTWK), a trailblazer in delivering cu...
|
 Clinical Study
Overview Wave Life Sciences has announced a significant milestone in gene therapy through its RestorAATion-2 trial, showcasing the first-ever therapeutic RNA editing in humans. This innovative approach targets Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder linked to lung and liver disease, through its ...
|
Our Most Popular Articles
|
 Product Service News
As the leaves turn and autumn whispers the arrival of new adventures, the RV industry gears up for one of its most anticipated events: the Hershey RV Show. This year, Winnebago Industries Inc. (NYSE: WGO) stands at the forefront of innovation and bold design, revealing a staggering lineup of nearly 150 new models fr...
|
 Clinical Study
In an exciting development in the field of obesity treatment, Skye Bioscience has announced the launch of its Phase 2 clinical trial, known as the CBeyond trial, to evaluate the efficacy and safety of its innovative CB1 inhibitor, nimacimab. This clinical trial aims to address one of the most pressing health concern...
|
 Product Service News
CSIMarket.com Factual - September 11, 2024 B2Gold Corp Engages in Accord with the Government of Mali Regarding the Fekola Complex In the year of our Lord, 2024, on the 11th day of September, B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G), a Canadian entity based in the city of Vancouver, Britons of C...
|
More News
|
 Partnership
Vimeo’s Cinematic Ambitions Amid Market Headwinds: A Balancing ActIn a bid to solidify its standing in the competitive video-on-demand market, Vimeo has recently announced a strategic partnership with the European Film Academy (EFA) aimed at celebrating and promoting the art of filmmaking. This initiative will se...
|
 Contract
iPower Inc. Achieves Key Milestone with First Purchase Order Shipment from Vietnam In a significant development within the e-commerce landscape, iPower Inc. (Nasdaq: IPW), a technology and data-driven ecommerce services provider, has announced the successful shipment of its first purchase order (PO) from Vietnam. Th...
|
 Business Update
Adicet Bio Secures FDA Approval for Pioneering Trials of ADI-001 in Rare Autoimmune Disorders: Idiopathic Inflammatory Myopathy and Stiff Person Syndrome to ADI-001 and Its Potential Impact In an exciting development for the treatment of rare autoimmune disorders, Adicet Bio, Inc. a leading clinical-stage biotechn...
|
 Clinical Study
Corbus Pharmaceuticals Advances in Oncology with CRB-701 NORWOOD, Mass. Oct. 16, 2024 In a significant milestone for cancer therapeutics, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has completed enrollment for the dose escalation stage of its Phase 1 clinical trial for CRB-701 (SYS6002), an innovative ...
|
 Product Service News
Enphase Energy Expands Footprint with Launch of IQ8X Microinverters in Europe and Beyond Enphase Energy, Inc. a leading global player in energy technologies, is making significant strides in the solar industry with the launch of its latest product, the IQ8X Microinverter. On October 16, 2024, the company announced t...
|
 Product Service News
An Extensive for CSIMarket.com In a significant stride for fibromyalgia treatment, Tonix Pharmaceuticals recently announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational medication, TNX-102 SL. This announcement comes on the heels of two succ...
|
 Product Service News
Forge Nano Secures $10M Investment from GM Ventures Amid Booming Automotive Sector PerformanceIn a significant development in the materials science and automotive industries, Forge Nano, Inc. a leading innovator in material optimization, has announced a $10 million investment from GM Ventures, the venture capital a...
|
 Business Update
General Motors Invests $625 Million in Joint Venture with Lithium Americas to Develop Nevada s Thacker Pass Project In a significant strategic move, General Motors (GM) and Lithium Americas Corp. have announced a new investment agreement to form a joint venture aimed at funding, developing, constructing, and operati...
|
 Product Service News
: Context Therapeutics Inc. a biopharmaceutical company focused on developing innovative therapies for solid tumors, has announced the presentation of a poster highlighting its clinical asset, CTIM-76. This bispecific antibody targeting Claudin 6 and CD3 will be featured at the Society for Immunotherapy of Cancers...
|
 Product Service News
Optimizing Pharmaceutical Success: Scilex Holding Company Explores Strategic Opportunities for Subsidiary Growth In a bold move, Scilex Holding Company (Nasdaq: SCLX), a vanguard in the pharmaceutical industry, has announced intentions to bolster the potential of its wholly owned subsidiary, Scilex Pharmaceuticals I...
|
 Clinical Study
In a significant stride towards advancing the treatment landscape for Thyroid Eye Disease (TED), ACELYRIN, INC. has officially announced the formation of a Scientific and Patient Advisory Board. This coalition is comprised of prominent voices within the realms of clinical research and patient advocacy, who will prov...
|
 Clinical Study
Exploring Novel Therapeutic Frontiers: Apellis Pegcetacoplan Takes Centre Stage at ASN Kidney Week In a pivotal revelation for the nephrology community, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has unveiled its latest findings in the Phase 3 VALIANT study involving pegcetacoplan, targeting two formidable renal ...
|
 Clinical Study
Trailblazing in Autoimmune Therapies: Cullinan Therapeutics Garners FDA IND Clearance for CLN-978 in Lupus Treatment In a significant stride for autoimmune disease treatment, Cullinan Therapeutics Inc. recently received FDA clearance for its Investigational New Drug (IND) application to administer CLN-978 subcutaneously in patients with moderate to severe systemic lupus erythematosus (SLE). This pioneering decision marks CLN-978 as the first development-stage CD19 T cell engager to receive IND clearance from the U.S. FDA for autoimmune diseases, signifying a potential breakthrough in targeting debilitating immune disorders. Breaking New Ground with CLN-978 CLN-978 represents a novel approach by leveraging the innovative T cell engaging mechanisms aimed at diseases characterized by systemic immune dysregulation, such as lupus. Systemic lupus erythematosus, an unpredictable and challenging autoimmune condition, affects numerous organ systems with varied symptoms, ranging from mild to severely debilitating. Current treatment regimens often involve generalized immunosuppression, leading to numerous side effects and variable patient outcomes. In contrast, CLN-978’s CD19 T cell engager mechanism targets B cells, a key player in the autoimmune response tied to lupus. By employing this targeted strategy, CLN-978 holds promise to selectively mitigate the pathologic immune activity while preserving normal immune function, potentially redefining treatment paradigms and improving the quality of life for lupus patients.
|
 Announcement
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a forward-thinking company in the field of radiopharmaceuticals, has reached a significant milestone with the commencement of shipments and patient dosing from its newly inaugurated manufacturing facility in Somerset, New Jersey. As the company continues to spear...
|
 Announcement
In a pivotal development that stands to bolster the strategic growth s of Gyrodyne, LLC, the Supreme Court of the State of New York delivered a resounding victory for the company on October 16, 2024. The legal triumph came after the court dismissed a petition aimed at nullifying the approvals granted by the Town of ...
|
 Product Service News
In recent months, Descartes Systems Group (Nasdaq: DSGX), a leader in logistics technology, has made notable strides in enhancing the efficiency and reliability of freight and customer service operations across a range of industries. Three key announcements highlight the company s innovative applications of technolo...
|
|
|
|
|
